Enliven Therapeutics Inc. (Nasdaq: ELVN) reported this week that as of the end of 2025, the clinical-stage precision oncology company has $462.6 million in cash and equivalents, enough runway to fund ...
Industry participation is also expanding through the involvement of NEURA Robotics as the incubator’s first corporate sponsor. David Reger, founder and Chief Executive Officer of NEURA Robotics, said ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果